We are excited to announce the CNS Diseases Summit, to be held on September 11-12, 2017 in Boston, MA. This meeting provides an interactive learning and relationship-building forum for all players in the CNS field. Colleagues from industry, academia, government agencies, and financing bodies will gather at the interface of research, partnerships, funding, and commercialization to find ways to move forward in a field that has been troubled with clinical failures.
The program will provide a comprehensive look at the current state of CNS, from research to commercialization. Above all, this event will provide networking opportunities in an intimate and accessible environment.
We invite you to join us as we connect, build relationships, and seek new ways forward into the future of CNS research and development.
Joint Plenary Sessions:
I. Kick-off Keynote Session – Historical Perspective & State of the Industry
II. Award Ceremony & Closing Keynote Session – Predictions for future
III. Round Table Session: Neuroimaging & Translational Biomarkers
11th Neurodegenerative Diseases Research & Development
I. Experimental Therapeutics & Approaches in Alzheimer’s Disease
II. Advances in Parkinson’s Disease Research & Therapeutics
III. Next Frontier in Multiple Sclerosis to Limit or Reverse Neurodegeneration
IV. Therapeutics for Rare & Orphan Neurodegenerative Diseases
10th CNS Partnering & Deal-making
I. What sells in CNS – New Targets, Models, Assays, etc.
II. Partnering with Academia & CROs to Advance Research
III. CNS Perspectives from Venture Capital & Public Markets
IV. Technology Transfer & Licensing: Challenges & Opportunities
We hope to see you there!
The 2017 Advisory Committee
Amber Kempf at 626-256-6405 x110 or amber.kempf [at] gtcbio.com
For more information on Media Relations, please contact:
Jennifer Chu at 626-256-6405 x105 or jennifer.chu [at] gtcbio.com